Dengue is ranked by WHO as the most important mosquito-borne viral disease. One recent estimate reported up to 390 million infections annually, with almost 100 million having symptoms of infection. Global warming and intercontinental flights fuel the global spreading of this disease. The increasing incidences and global spreading cause significant productivity loss and healthcare costs, reportedly as much as $2.8B per year in the Americas. So far, there is no specific treatment or vaccine available to treat or prevent the disease.
BRM211 aims to be the first small molecule drug with anti-viral activity against all four major dengue serotypes (DENV1, DENV2, DENV3, and DENV4). Dengue is a systemic and dynamic disease. The first dengue infection is generally a self-limiting, acute febrile illness. Subsequent infection with a different serotype can lead to severe diseases such as Dengue Hemorrhagic Fever, Dengue Shock Syndrome and even death. BRM211 is targeted for once daily oral administration, with efficacy complementary to vaccines that are currently in development. BRM211 is expected to offer several advantages over vaccines including faster onset, lower cost, and no requirement for cold chain storage and transportation. Since most of dengue endemic areas are emerging economies where drug affordability and minimal storage requirement are critical for mass market access, BRM211 is anticipated to effectively answer the call of the unmet medical needs in dengue disease.